Baker Avenue Asset Management’s Royalty Pharma RPRX Stock Holding History

Baker Avenue Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$392K	Buy	6,991 +113	+2%	+$5.88K	0.01%	589
2026 Q1	$330K	Buy	+6,878	New	+$301K	0.01%	578
2023 Q4	–	Sell	-119	Closed	-$3.24K	–	1259
2023 Q3	$3.24K	Buy	119 +65	+120%	+$1.93K	﹤0.01%	1042
2023 Q2	$1.66K	Buy	54 +18	+50%	+$610	﹤0.01%	1031
2023 Q1	$1.3K	Sell	36 -2	-5%	-$74	﹤0.01%	1101
2022 Q4	$1.5K	Buy	+38	New	+$1.59K	﹤0.01%	993

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baker Avenue Asset Management's RPRX Position: Q2 2026 in Review

Baker Avenue Asset Management increased its Royalty Pharma (RPRX) stake by 1.6% in Q2 2026, buying an estimated $5.88K and bringing the position to 6,991 shares worth $392K. The position accounts for 0.01% of the portfolio, ranked #589.

Baker Avenue Asset Management first reported a position in RPRX in Q4 2022 and has held it in 6 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Baker Avenue Asset Management held 6,991 shares of Royalty Pharma worth $392K as of Q2 2026.
Baker Avenue Asset Management bought 113 Royalty Pharma shares in Q2 2026, an estimated $5.88K.
Royalty Pharma made up 0.01% of Baker Avenue Asset Management's portfolio in Q2 2026, its #589 holding.
Baker Avenue Asset Management first reported a position in Royalty Pharma in Q4 2022 and has held it in 6 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.